Cytogenetic Risk에 근거한 급성골수성백혈병의 공고요법에 관한 다기관 임상시험

초록

The treatment of acute myeloid leukemia (AML) over past 4 decades taught us the importance of cytogenetic pattern in the prediction of prognosis. We stratified AML into 4 groups, i.e. acute promyelocytic leukemia (t 15;17), good prognosis group [t (8;21), inv (16)], intermediate prognosis group (diploid), and poor prognostic group (-5, -7, del 5q, 3q, complex) and treated with different consolidation therapies accordingly. After remission induction, consolidation therapy consisted of 3 courses of idarubicin single agent for acute promyelocytic leukemia, 2 courses of cytarabine based chemotherapy, one in intermediate and the other in high dose, for good risk group, and 3 courses of cytarabine based chemotherapy including high dose cytarbine or autologous/allogeneic bone marrow transplant after 1 course of consolidation for intermediate or poor prognosis group. From January 2000 through March 2001, a total of 130 patients were enrolled for the study, and the results will be available soon. The trial is aimed at the development of least toxic and most effective treatment of acute myeloid leukemia.